Press Releases

Rain Therapeutics Announces Appointment of Robert Doebele, MD, PhD as Executive Vice President and Chief Scientific Officer

September 15, 2020

NEWARK, Calif., September 15, 2020 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today announced the appointment of Rain co-founder Robert Doebele, MD, PhD, as chief scientific officer (CSO). Dr. Doebele has served as chair of the scientific advisory board and acting CSO since Rain’s founding. He will now transition to Rain full-time in the executive vice president (EVP) and CSO role, departing his position at the University of Colorado, Denver as associate professor of medicine.  In his new role, Dr. Doebele will be responsible for leading Rain’s research and development efforts.

While at the University of Colorado, Dr. Doebele discovered NTRK1 fusions in lung cancer and pioneered the development of the pan-TRK inhibitors ARRY-470, subsequently renamed larotrectinib (VITRAKVI®) from Loxo Oncology, and entrectinib (ROZLYTREK®) from Ignyta Pharmaceuticals.

“Working with Bob since the founding of Rain has been a great privilege, and we are thrilled to officially welcome him in a full-time capacity,” said Avanish Vellanki, co-founder and chief executive officer of Rain. “As a visionary leader in the precision oncology space with unparalleled experience in developing tumor-agnostic approaches to cancer treatment, we are in keen anticipation of Bob’s impact on the corporate biotechnology industry post his departure from academia.”

Dr. Doebele added, “Rain is at a pivotal juncture in its evolution, and I am excited to transition full time to the company. Rain’s pipeline, which now includes RAIN-32, a potent MDM2 inhibitor, and a RAD52 inhibitor program in addition to our first clinical candidate, Tarlox, has the potential to make a transformative impact in the lives of patients with difficult-to-treat cancers. I look forward to leading the team as we develop tumor-agnostic, biomarker-driven trials to advance our targeted oncology candidates.”

Dr. Doebele co-founded Rain Therapeutics in April 2017 and currently serves as chair of the scientific advisory board. Prior to joining Rain full time, Dr. Doebele served as associate professor of medicine in the division of medical oncology at the University of Colorado School of Medicine, director of the Thoracic Oncology Research Initiative at the University of Colorado Cancer Center and as principle investigator for the University of Colorado Lung Cancer Specialized Program of Research Excellence.   

In addition, he served as a senior editor of the AACR journal, Clinical Cancer Research and was elected to the American Society for Clinical Investigation in 2018. Dr. Doebele received his AB in molecular biology from Princeton University and received his MD and PhD in immunology from the University of Pennsylvania. He conducted his internal medicine residency and medical oncology fellowship at the University of Chicago.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing targeted therapies for patients with cancer. Rain’s lead program is RAIN-32, a small molecule MDM2 inhibitor for patients with well-differentiated and de-differentiated liposarcoma, and other indications exhibiting MDM2 gene amplification or overexpression. RAIN-32 has completed clinical trials in certain solid tumors and hematological malignancies and has received FDA Orphan Drug Designation for patients with liposarcoma. Tarloxotinib, a hypoxia-activated pan-HER inhibitor is in clinical trials for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations and HER2 activating mutations, as well as a tumor-agnostic cohort for patients with NRG1, EGFR, HER2, and HER4 fusions. Rain is also developing a potential first-in-class inhibitor of RAD52 in the DNA Damage Response (DDR) pathway as a synthetic lethal strategy for tumors with BRCA1/2 mutations.   For more information, visit www.rainthera.com.

Media Contact for Rain

Cait Williamson, PhD
LifeSci Communications
+1.646.751.4366
cait@lifescicomms.com

Rain Therapeutics to Present at Citi’s 15th Annual BioPharma Virtual Conference

September 3, 2020

NEWARK, Calif., September 3, 2020 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today announced that Avanish Vellanki, chairman and chief executive officer of Rain, will present a corporate overview at Citi’s 15th Annual BioPharma Virtual Conference being held September 8-10, 2020.

Citi’s Annual BioPharma Conference
Date: Tuesday, September 8
Time: 10:05 a.m. EDT

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing targeted therapies for patients with cancer. Rain’s lead program is RAIN-32, a small molecule MDM2 inhibitor for patients with well-differentiated and de-differentiated liposarcoma, and other indications exhibiting MDM2 gene amplification or overexpression. RAIN-32 has completed clinical trials in certain solid tumors and hematological malignancies.  Tarloxotinib, a hypoxia-activated pan-HER inhibitor is in clinical trials for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations and HER2 activating mutations, as well as a tumor-agnostic cohort for patients with NRG1, EGFR, HER2, and HER4 fusions. Rain is also developing a potential first-in-class inhibitor of RAD52 in the DNA Damage Response (DDR) pathway as a synthetic lethal strategy for tumors with BRCA1/2 mutations.   For more information, visit www.rainthera.com.

Media Contact for Rain

Cait Williamson, PhD
LifeSci Communications
+1.646.751.4366
cait@lifescicomms.com

Rain Therapeutics Closes $63 Million Series B Financing

September 3, 2020

Proceeds to Support Advancement of Expanded Pipeline of Targeted Cancer Therapies

NEWARK, Calif., September 3, 2020 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, has closed a $63 million Series B financing. The financing was led by Boxer Capital and followed by new investors Cormorant Asset Management, Samsara BioCapital, Janus Henderson Investors and Logos Capital, with continued support and participation by existing investors BVF Partners L.P., Perceptive Advisors and other investors. In conjunction with the financing, Boxer Capital will appoint a representative to the Rain board of directors.

“We view this lineup of extraordinary investors as validation of the opportunity of the Rain pipeline across a range of cancers leveraging a precision oncology strategy,” said Avanish Vellanki, cofounder and chief executive officer of Rain Therapeutics.

Rain plans to use the proceeds to advance its pipeline of targeted cancer therapies and general corporate purposes.  These programs include RAIN-32, a potent and selective small molecule MDM2 inhibitor recently licensed from Daiichi Sankyo Company, Limited that has been evaluated in clinical trials for certain solid and hematological malignancies.

Rain is also pursuing the development of a selective RAD52 inhibitor, which represents a potential synthetic lethal strategy for tumors with BRCA1/2 mutations. Rain’s initial program, tarloxotinib, a pan-HER inhibitor, is currently being evaluated in Phase 2 clinical trials.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing targeted therapies for patients with cancer. Rain’s lead program is RAIN-32, a small molecule MDM2 inhibitor for patients with well-differentiated and de-differentiated liposarcoma, and other indications exhibiting MDM2 gene amplification or overexpression. RAIN-32 has completed clinical trials in certain solid tumors and hematological malignancies.  Tarloxotinib, a hypoxia-activated pan-HER inhibitor is in clinical trials for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations and HER2 activating mutations, as well as a tumor-agnostic cohort for patients with NRG1, EGFR, HER2, and HER4 fusions. Rain is also developing a potential first-in-class inhibitor of RAD52 in the DNA Damage Response (DDR) pathway as a synthetic lethal strategy for tumors with BRCA1/2 mutations.   For more information, visit www.rainthera.com.

Media Contact for Rain

Cait Williamson, PhD
LifeSci Communications
+1.646.751.4366
cait@lifescicomms.com

Rain Therapeutics Announces Exclusive License to the Clinical-Stage MDM2 Inhibitor, DS-3032 (Milademetan) from Daiichi Sankyo

September 2, 2020

NEWARK, Calif., September 2, 2020 — Rain Therapeutics Inc. (“Rain”), a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today announced it has licensed worldwide rights to a clinical stage, small molecule, oral MDM2 inhibitor, DS-3032 (milademetan) from Daiichi Sankyo Company, Limited. Rain will re-designate the program as RAIN-32.

RAIN-32 is a potent and selective MDM2 inhibitor that has been evaluated in clinical trials for solid tumors and hematologic malignancies. The profile and dosing schedule of RAIN-32 may lend a differentiated tolerability profile, enabling longer-term therapy as compared to other MDM2 programs in development.

“We’re excited to add RAIN-32, a clinical program with the potential to significantly impact cancers characterized by MDM2 amplification or overexpression, to Rain’s pipeline of targeted cancer therapies,” said Avanish Vellanki, cofounder and chief executive officer of Rain Therapeutics. “Daiichi Sankyo has done extensive work that we intend to build upon as we implement a biomarker-driven strategy to complete RAIN-32’s development.”

MDM2 has emerged as a potentially valuable target for cancer therapies due to its inhibitory effects on p53, a critical tumor suppressor. Rain intends to evaluate RAIN-32 in multiple indications where patients demonstrate MDM2 gene amplification or overexpression, with an initial focus on liposarcoma, where two-thirds of patients display MDM2 amplification.

Robert Doebele, MD, PhD, cofounder of Rain Therapeutics, added, “We hope to pursue a rapid registrational path for RAIN-32 in a challenging tumor type that lacks effective therapies, and look forward to rationally developing RAIN-32 for additional oncology indications where MDM2 activity plays a central role.”

Rain anticipates the presentation of clinical data from the ongoing Daiichi Sankyo clinical trial in patients with advanced solid tumors at an upcoming medical conference.

Rain has licensed global rights for all indications of RAIN-32. Deal terms from the license agreement were not disclosed.

About RAIN-32

RAIN-32 has been evaluated in patients with various solid tumors, acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). RAIN-32 also has been evaluated in continuous and intermittent dose schedules that may offer a differentiated tolerability profile as compared to other MDM2 programs.

Two clinical studies for RAIN-32 are ongoing, including a study evaluating the safety and efficacy of RAIN-32 in patients with liposarcoma and in patients with FLT3-ITD AML treated with RAIN-32 and the FLT3 inhibitor, quizartinib. In addition, multiple investigator sponsored studies are being conducted by MD Anderson Cancer Center (MDACC) as well as National Cancer Center Hospital (NCCH) in Tokyo, Japan. 

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing targeted therapies for patients with cancer. Rain is investigating tarloxotinib in a Phase 2 clinical trial, a hypoxia-activated prodrug of a potent pan-ErbB inhibitor as a treatment for non-small cell lung cancer patients with EGFR exon 20 insertions and HER2 mutations as well as any solid tumors with gene fusions involving NRG1, EGFR, HER2, and HER4. Rain Therapeutics Inc. has worldwide development and commercialization rights for tarloxotinib. Rain is also developing novel inhibitors of RAD52 in the DNA Damage Response (DDR) pathway as a synthetic lethal strategy in BRCA1/2-deficient tumors.  For more information, visit www.rainthera.com.

Media Contact for Rain

Cait Williamson, PhD
LifeSci Communications
+1.646.751.4366
cait@lifescicomms.com

Rain Therapeutics Announces License Agreement for the Development of Proprietary RAD52 Inhibitors in the DNA Damage Response Pathway

August 25, 2020

Agreement Expands Rain’s Biomarker-Driven Pipeline to Include Synthetic Lethal Strategies in Homologous Recombination (HR) Deficient Cancers

NEWARK, Calif., August 25, 2020 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today announces the signing of an exclusive, worldwide license agreement of a Drexel University research program to Rain for small molecule inhibitors of RAD52, a critical molecule involved in the DNA damage response (DDR) pathway. The agreement expands Rain’s targeted oncology pipeline to include synthetic lethal strategies for the treatment of cancers associated with mutations in the DDR pathway, including breast and ovarian cancers characterized by BRCA1/2 mutations.

“Rain was founded with the goal of developing biomarker-driven, tumor-agnostic approaches to cancer treatment, and we are thrilled to be building on that vision today with the addition of Drexel’s RAD52 program to our pipeline,” said Avanish Vellanki, cofounder and chief executive officer of Rain Therapeutics. “RAD52 is a novel and rational oncology target, and we’ve been very impressed with the advances in the field made by Drexel researchers.”

RAD52 is involved in several DDR pathways, and RAD52 inactivation is synthetically lethal in cancer cells with BRCA1/2 and other homologous recombination (HR) gene mutations. Drexel’s RAD52-targeted inhibitors have evidenced potent in vitro and in vivo activity in BRCA1-deficient xenograft models, alone and in combination with PARP inhibitors.

There are currently no clinical programs in development targeting RAD52.

Dr. Alexander Mazin, the principal investigator on the RAD52 project at Drexel added, “Targeting RAD52 has been a major focus of our research efforts, and we are excited that this work is moving forward towards a targeted therapy for BRCA-deficient cancers. There is great potential for precision medicine therapies for patients with these difficult-to-treat cancers, and we look forward to collaborating with Rain to bring this important science to the bedside as quickly and safely as possible.”

Under the terms of the agreement, Rain will support ongoing research at Drexel University in addition to conducting independent research to optimize candidates for clinical development. Drexel University will also receive milestone payments and royalties based on successful development and commercialization of proprietary programs.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing targeted therapies for patients with cancer. Rain is developing tarloxotinib, a hypoxia-activated prodrug of a potent pan-ErbB inhibitor as a treatment for non-small cell lung cancer patients with EGFR exon 20 insertions and HER2 mutations as well as any solid tumors with gene fusions involving NRG1, EGFR, HER2, and HER4. Rain Therapeutics Inc. has worldwide development and commercialization rights for tarloxotinib. For more information, visit www.rainthera.com

Media Contact for Rain

Cait Williamson, Ph.D.
LifeSci Communications
+1.646.751.4366
cait@lifescicomms.com

Rain Therapeutics Presents Preclinical Data on Lead Candidate Tarloxotinib at the American Association for Cancer Research (AACR) Annual Meeting

April 3, 2019

NEWARK, Calif., April 3, 2019 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced new preclinical data on tarloxotinib (Tarlox) presented at the American Association for Cancer Research (AACR) Annual Meeting 2019, held in Atlanta, Georgia from March 29-April 3, 2019. Three poster presentations detailed: 1) potent in vitro activity of Tarlox in a variety of EGFR and HER2 mutations, 2) data demonstrating that STEAP4 expression may serve as an additional biomarker to predict sensitivity to Tarlox in clinical trials, and 3) results of a comprehensive set of studies revealing the potential for Tarlox in treating NRG1 altered cancers.   

Key findings from Rain presentations include: 

  • Tarlox significantly inhibited tumor growth and regressed tumors in an NRG1 ovarian cancer patient-derived xenograft model (100% reduction in tumor size in the group dosed with 48 mg/kg of Tarlox as compared to a 150% increase in tumor size in the control group). 
  • Tarlox inhibits proliferation of EGFR and HER2 Exon 20 insertion mutations and osimertinib-resistant mutations in vitro, demonstrating potent activity and potential to treat EGFR-driven cancers that have been unresponsive to the current standard of care.
  • High STEAP4 expression is detected in EGFR mutant (del19, L858R and exon 20 insertion) lung cancer FFPE samples, and STEAP4 gene expression levels are significantly increased in EGFR-mutant non-small cell lung cancer samples as compared to wild type (p <0.05 in three cohorts of lung cancer datasets)

“Taken together, these exciting results provide strong evidence for the broad potential of Tarlox as a targeted cancer therapy,” said Avanish Vellanki, chief executive officer of Rain Therapeutics. “These data are encouraging as we continue our Phase 2 clinical trial of Tarlox in non-small cell lung cancer with EGFR exon 20 insertion and HER2 activating mutations, and we are looking forward to continuing to advance Tarlox through clinical development.”

Copies of the presentation materials can be accessed by visiting the Publications section of the Rain website.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB inhibitor in development as a treatment for non-small cell lung cancer patients with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc. has worldwide development and commercialization rights for Tarloxotinib. For more information, visit www.rainthera.com

Media Contact

Cait Williamson, Ph.D.
LifeSci Public Relations
+1.646.751.4366
cait@lifescipublicrelations.com

Rain Therapeutics Presents Preclinical Activity of Tarloxotinib in NRG1 Fusion Cancers at the Annual American Association for Cancer Research (AACR) Meeting

April 2, 2019

Data support expanding clinical development of tarloxotinib to patients with NRG1 fusion and rearranged cancers with a tumor agnostic, basket strategy

NEWARK, Calif., April 2, 2019 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced that it presented new preclinical data on tarloxotinib (Tarlox), a hypoxia-activated pan-HER inhibitor, in NRG1 fusion positive cancers at the American Association for Cancer Research (AACR) Annual Meeting 2019, held in Atlanta, Georgia from March 29-April 3, 2019. These data support a potential addititional indication for Rain. Rain is currently conducting a Phase 2 clinical trial of Tarlox in EGFR Exon 20 and HER2 mutation positive non-small cell lung cancer.

“The activity observed by Tarlox in NRG1 fusion models is very exciting,” said Avanish Vellanki, chief executive officer of Rain Therapeutics. “The potency of tarlox observed across various in vitro and patient-derived animal studies was intuitive as NRG1 tumors rely on HER-signaling.”

Robert Doebele, MD, PhD, acting chief science officer of Rain Therapeutics continued, “NRG1 fusion positive cancers resemble NTRK fusion tumors in their addiction to a single oncogenic driver and their presence across multiple tumor types. Like EGFR and HER2 exon 20 insertion mutations, NRG1 fusions represent cancers that are difficult to drug without significant toxicity, hence providing another opportunity for the hypoxia-activated strategy of tarloxotinib.”  

NRG1 encodes the HER3 ligand neuregulin 1. NRG1 gene fusions are oncogenic drivers that overexpress the HER3 ligand, leading to heterodimerization of HER2/HER3 and activation of downstream ERK, PI3K–AKT and NF-kB pathways. NRG1 fusions are particularly enriched in invasive mucinous adenocarcinoma of the lung where they are found in 27-31% of cases and have also been reported in other cancer types with an overall incidence of 0.2% across all solid tumors. The preclinical studies presented at AACR demonstrate, among other significant findings, that Tarlox significantly inhibited tumor growth and regressed tumors in an NRG1 ovarian cancer patient-derived xenograft model. There was a 100% reduction in tumor size in the group dosed with 48 mg/kg of Tarlox as compared to a 150% increase in tumor size in the control group.

Data from the preclinical study were presented in a poster entitled “Tarloxotinib Exhibits Potent Activity in NRG1 Gene Fusion Positive Cancers.” A copy of the presentation materials can be accessed by visiting the Publications section of the Rain website.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB inhibitor in development as a treatment for non-small cell lung cancer patients with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc. has worldwide development and commercialization rights for Tarloxotinib. For more information, visit www.rainthera.com

Media Contact

Cait Williamson, Ph.D.
LifeSci Public Relations
+1.646.751.4366
cait@lifescipublicrelations.com

Rain Therapeutics Announces First Patient Dosed in Phase 2 Trial of Tarloxotinib for the Treatment of Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertion or HER2-Activating Mutations

March 19, 2019

First patient dosing comes within ten months of the Series A financing

NEWARK, Calif., March 19, 2019 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced that it has dosed the first patient in its Phase 2 clinical trial of tarloxotinib (Tarlox).  The start of the Phase 2 trial comes within 10 months of the Company announcing its Series A financing.

The open-label RAIN-701 study will evaluate the objective response to Tarlox in lung cancer patients with EGFR Exon 20 insertion or HER2-activating mutations. Tarlox is a hypoxia-activated prodrug of a pan-HER inhibitor.

“The dosing of the first patient in our Phase 2 trial is an important milestone for Rain as we advance Tarlox through clinical development,” said Avanish Vellanki, chief executive officer of Rain Therapeutics. “We continue to be very excited about the opportunity for Tarlox in all HER-addicted tumors, especially in patients with limited treatment options.”

The RAIN-701 study is a Phase 2 open-label trial designed to evaluate the objective response rate of Tarlox administered once weekly by intravenous administration. The trial will enroll approximately 40 patients at sites across the U.S., Canada and Hong Kong who have been diagnosed with NSCLC confirmed to possess EGFR exon 20 insertion mutations or HER2-activating mutations.

“Lung cancer patients with HER-family exon 20 mutations are in great need of effective and tolerable treatment options,” said lead investigator, Stephen V. Liu, MD, associate professor of medicine at Georgetown Lombardi Comprehensive Cancer Center. “As part of our mission, we are committed to engaging in essential clinical research to develop additional therapies for these patients.”

More information can be found at www.rainthera.com/patients/ and at www.clinicaltrials.gov (NCT03805841). 

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, tarloxotinib, is a hypoxia-activated prodrug of a potent pan-HER tyrosine kinase inhibitor in development as a treatment for non-small cell lung cancer patients. Rain Therapeutics Inc. has worldwide development and commercialization rights for tarloxotinib. For more information, visit www.rainthera.com.

Media Contact

Cait Williamson, Ph.D.
LifeSci Public Relations
+1.646.751.4366
cait@lifescipublicrelations.com

Rain Therapeutics to Present Data on Tarloxotinib at the American Association for Cancer Research (AACR) Annual Meeting 2019

February 28, 2019

NEWARK, Calif., February 28, 2019 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced presentations of preclinical data from ongoing studies of Rain’s lead candidate, tarloxotinib, at the American Association for Cancer Research (AACR) Annual Meeting 2019 being held March 29-April 3, 2019 in Atlanta, Georgia. Poster presentations will feature data detailing in vitro activity of tarloxotinib for a variety of EGFR/ HER2 mutations and in vitro and in vivo efficacy in NRG1 altered cancers, as well as data demonstrating that STEAP4 expression can serve as an additional biomarker to predict sensitivity to tarloxotinib therapy in upcoming clinical trials.

Details on the presentations are as follows: 

Presentation Title: Tarloxotinib exhibits potent activity in NRG1 fusion and rearranged cancers
Presenter: Vijaya Tirunagaru, Ph.D, Rain Therapeutics
Poster Session Date and Time: Monday, April 1, 2019, 1:00 p.m. – 5:00 p.m. EDT
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 15

Presentation Title: Potent in vitro activity of Tarloxotinib for EGFR C797S and other mutations refractory to current EGFR tyrosine kinase inhibitors
Presenter: Kenichi Suda, M.D., Kindai University Faculty of Medicine
Poster Session Date and Time: Monday, April 1, 1:00 p.m. – 5:00 p.m. EDT
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 15

Presentation Title: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers
Presenter: Vijaya Tirunagaru, Ph.D, Rain Therapeutics
Poster Session Date and Time: Tuesday, April 2, 2019, 1:00 p.m. – 5:00 p.m. EDT
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 21

Additional details can be found on the conference website. A copy of presentation materials can be accessed by visiting the Science and Publications section of the Rain Therapeutics website after the presentations conclude.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB inhibitor in development as a treatment for non-small cell lung cancer patients with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc. has worldwide development and commercialization rights for Tarloxotinib. For more information, visit www.rainthera.com

Media Contact

Cait Williamson, Ph.D.
LifeSci Public Relations
+1.646.751.4366
cait@lifescipublicrelations.com


Download

Rain Therapeutics Announces Presentations on Tarloxotinib at the 30th EORTC-NCI-AACR Symposium

November 6, 2018

FREMONT, Calif., November 6, 2018 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced presentations of preclinical data from ongoing studies of Rain’s lead candidate, tarloxotinib, at the 30th annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held November 13-16, 2018 in Dublin, Ireland. Rain collaborators at the University of Auckland and the University of Colorado, Denver will present three posters detailing the efficacy of tarloxotinib in preclinical models.

Details on the presentations are as follows:

Presentation Title: Anti-tumor activity of tarloxotinib, a hypoxia-activated EGFR/HER2 TKI, in HER2 driven cell lines
Presenter: Adriana Estrada-Bernal, Ph.D., University of Colorado, Denver
Date: November 13, 2018
Poster Viewing Time: 12:00 p.m. – 6:30 p.m. GMT

Presentation Title: The hypoxia-activated EGFR/HER2 inhibitor Tarloxotinib is activated by the plasma membrane reductase STEAP4
Presenter: Shevan Silva, Ph.D., University of Auckland
Date: November 16, 2018
Poster Viewing Time: 10:00 a.m. – 2:00 p.m. GMT

Presentation Title: Targeting tumour hypoxia with tarloxotinib improves the therapeutic efficacy of checkpoint blockade
Presenter: Regan Zhe Fu, MSc, University of Auckland
Date: November 16, 2018
Poster Viewing Time: 10:00 a.m. – 2:00 p.m. GMT

Additional details can be found on the conference website. A copy of presentation materials can be accessed by visiting the Science and Publications section of the Rain Therapeutics website after the presentations conclude.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB inhibitor in development as a treatment for non-small cell lung cancer patients with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc. has worldwide development and commercialization rights for Tarloxotinib through an exclusive license from the University of Auckland. For more information, visit www.rainthera.com

About the Translational Therapeutics Team, University of Auckland.

The Translational Therapeutics Team is a oncology research group lead by Associate Professors Adam Patterson and Jeff Smaill that specialize in all aspects of the design and development of hypoxia activated prodrugs. The team is based in the Auckland Cancer Society Research Centre, within the Faculty of Medical and Health Sciences, located at The University of Auckland. Funding support is primarily through the Health Research Council of New Zealand, the Maurice Wilkins Centre for Molecular Biodiversity and Cancer Society Auckland and Northland.

About the Doebele Laboratory, University of Colorado, Denver

The Doebele laboratory at the University of Colorado Anschutz Medical Campus focuses on  generating unique patient-derived cancer models, including human cancer cell lines, to study specific oncogene-driven cancers. The lab has successfully defined intrinsic and acquired resistance mechanisms for ALK and ROS1-driven cancers and was the first to identify NTRK1 gene fusions in lung cancer, generating the pre-clinical data that led to the development of TRK inhibitors for lung and other cancers harboring NTRK gene fusions. More recently, the lab has turned to tackling the clinical problem of treating EGFR exon 20 and HER2 exon 20 mutations as well as other HER-family receptor tyrosine kinase-driven cancers. Ultimately, the lab’s goal is to advance personalized medicine through the identification, analysis, and rational targeting of driver oncogenes in cancer in order to improve the clinical outcomes of patients.

Media Contact

Cait Williamson, Ph.D.
LifeSci Public Relations
+1.949.290.4945
cait@lifescipublicrelations.com


Download

Lori Kunkel, M.D. Joins the Rain Therapeutics Scientific Advisory Board (SAB)

October 1, 2018

FREMONT, Calif. – October 1, 2018 – Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, announces the addition of Lori Kunkel, M.D., to its scientific advisory board. Dr. Kunkel is a clinical drug development specialist and strategic advisor to targeted and immuno-oncology biotechnology companies with over twenty years of experience in the oncology space.

“We are excited and privileged to have Dr. Kunkel’s help as part of our scientific advisory board,” said Avanish Vellanki, chief executive officer of Rain Therapeutics. “Dr. Kunkel’s decades of experience in clinical oncology drug development will be invaluable as we continue to advance our lead asset, tarloxotinib, and expand our pipeline with additional targeted therapies.”

Dr. Kunkel currently serves on the board of directors of Loxo Oncology, Inc., Curis, Inc., Maverick Therapeutics, Inc.,and Tocagen, Inc. Previously she has served as acting chief medical officer of Loxo Oncology, Inc., chief medical officer of Pharmacyclics, LLC, and Proteolix, Inc. and vice president of clinical development at Xencor, Inc. Earlier in her career she was a clinical scientist at Genentech, where she worked on the development of RITUXAN ®.

“Dr. Kunkel’s approach to drug development is very similar to ours, and Rain will undoubtedly benefit from her perspectives across the various initiatives ongoing at the Company,” said Robert Doebele, M.D., Ph.D., Rain’s co-founder and chairperson of the scientific advisory board.

Prior to her career in biotechnology, Dr. Kunkel spent a decade in academic medicine as a faculty member at the Bone Marrow Transplant Unit in the Division of Hematology/Oncology at University of California, Los Angeles. She received her medical degree from University of Southern California and her bachelor’s degree in biology from University of California, San Diego. She is board certified in internal medicine and has held board certifications in hematology and oncology.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent HER inhibitor in development as a treatment for non-small cell lung cancer patients with Exon 20 insertion mutations. Rain Therapeutics Inc. has worldwide development and commercialization rights for Tarloxotinib through an exclusive license from the University of Auckland. For more information, visit www.rainthera.com

Media Contact

Cait Williamson, Ph.D.
LifeSci Public Relations
+1.646.751.4366
cait@lifescipublicrelations.com


Download

Rain Therapeutics Announces Collaborator Presentations on Tarloxotinib at Two Upcoming Conferences

August 22, 2018

FREMONT, Calif., August 22, 2018 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced presentations of preclinical data by its collaborator, the University of Auckland, from ongoing studies of Rain’s lead candidate, tarloxotinib, at the New Zealand Society for Oncology Conference being held August 24-25, 2018 and the Queenstown Molecular Biology Meeting being held August 27-29, 2018, both in Queenstown, NZ. The poster presentations describe the plasma membrane reductase responsible for the activation of tarloxotinib exclusively in hypoxic environments. This unique characteristic increases the specificity of tarloxotinib for cancer cells, making it an ideal candidate for the treatment of EGFR Exon 20 mutation-driven non-small cell lung cancer.

Details on the presentations by the University of Auckland’s Translational Therapeutics team are as follows:

New Zealand Society for Oncology Conference

Poster Presentation Title: Discovery of the plasma membrane reductase responsible for the activation of the cell-excluded hypoxia-activated prodrug Tarloxotinib
Presenter: Shevan Silva
Date/Time: August 24, 2018 at 4:45 p.m. NZST
Location: Queenstown Memorial Centre

Queenstown Molecular Biology Meeting

Poster Presentation Title: Discovery of the plasma membrane reductase responsible for the activation of the cell-excluded hypoxia-activated prodrug Tarloxotinib
Presenter: 
Shevan Silva
Date/Time: August 28, 2018 at 4:30 p.m. NZST
Location: Rydges Hotel, Queenstown

Additional details can be found on the New Zealand Society for Oncology website and the Queenstown Molecular Biology Meeting website. A copy of presentation materials can be accessed by visiting the Science and Publications section of the Rain website after the presentations conclude.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB inhibitor in development as a treatment for non-small cell lung cancer patients with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc. has worldwide development and commercialization rights for Tarloxotinib through an exclusive license from the University of Auckland. For more information, visit www.rainthera.com

About the Translational Therapeutics Team, University of Auckland.

The Translational Therapeutics Team is a oncology research group lead by Associate Professors Adam Patterson and Jeff Smaill that specialize in all aspects of the design and development of hypoxia activated prodrugs. The team is based in the Auckland Cancer Society Research Centre, within the Faculty of Medical and Health Sciences, located at The University of Auckland. Funding support is primarily through the Health Research Council of New Zealand, the Maurice Wilkins Centre for Molecular Biodiversity and Cancer Society Auckland and Northland.

Media Contact

Cait Williamson, Ph.D.
LifeSci Public Relations
+1.949.290.4945
cait@lifescipublicrelations.com


Download

Rain Therapeutics Announces Collaborator Presentations on Tarloxotinib at the 5th International Conference on Tumor Microenvironment and Cellular Stress

June 5, 2018

FREMONT, Calif., June 5, 2018 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced presentations of preclinical data by its collaborator, the University of Auckland, from ongoing studies of Rain’s lead candidate, Tarloxotinib, at the 5th International Conference on Tumor Microenvironment and Cellular Stress: Signalling Metabolism, Imaging and Therapeutic Targets being held June 8-13, 2018 in Chania, Crete, Greece. An oral presentation will detail the discovery of the plasma membrane reductase responsible for activating Tarloxotinib at the site of the tumor, and a poster presentation will discuss data collected in studies of Tarloxotinib that reveal favorable in vivo properties to be a treatment strategy for  patients with EGFR / HER Exon 20 insertion mutations in non-small cell lung cancer (NSCLC).

Details on the presentations by the University of Auckland’s Translational Therapeutics team are as follows:

Poster Presentation Title: Hypoxia tumour targeting with Tarloxotinib to improve clinical outcomes for patients with EGFR-dependent malignancies
Presenter: Victoria Jackson-Patel
Date/Time: June 9, 2018 at 10:30 am EEST

Oral Presentation Title: Discovery of the plasma membrane reductase responsible for the activation of the cell-excluded hypoxia-activated prodrug Tarloxotinib
Session: Session XI: Clinical-Therapeutic implications
Presenter: Adam V Patterson, Ph.D.
Date/Time: June 12, 2018 at 1:30 pm EEST

Additional details can be found on the conference website. A copy of presentation materials can be accessed by visiting the Science and Publications section of the Rain website after the presentations conclude.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB inhibitor in development as a treatment for non-small cell lung cancer patients with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc. has worldwide development and commercialization rights for Tarloxotinib through an exclusive license from the University of Auckland. For more information, visit www.rainthera.com

About the Translational Therapeutics Team, University of Auckland.

The Translational Therapeutics Team is a oncology research group lead by Associate Professors Adam Patterson and Jeff Smaill that specialize in all aspects of the design and development of hypoxia activated prodrugs. The team is based in the Auckland Cancer Society Research Centre, within the Faculty of Medical and Health Sciences, located at The University of Auckland. Funding support is primarily through the Health Research Council of New Zealand, the Maurice Wilkins Centre for Molecular Biodiversity and Cancer Society Auckland and Northland.

Media Contact

Cait Williamson, Ph.D.
LifeSci Public Relations
+1.949.290.4945
cait@lifescipublicrelations.com


Download

Rain Therapeutics Closes $18 Million Series A Financing

May 21, 2018

FREMONT, Calif., May 21, 2018 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced the closing of a tranched Series A financing of $18.4 million. The financing was led by San Francisco-based, Biotechnology Value Fund (BVF) and followed by Perceptive Advisors, Auckland UniServices Limited’s Inventors Fund and other private investors. BVF’s Gorjan Hrustanovic, Ph.D., will join the Rain Board of Directors in conjunction with the financing. The Series A round follows a $1 million convertible note financing completed in late-2017.

Rain plans to use the proceeds to advance the clinical development of its lead program, Tarloxotinib (Tarlox), in patients with EGFR and ErbB Exon 20 insertion mutations in non-small cell lung cancer (NSCLC). The company intends to commence a Phase 2 study in patients with EGFR and ErbB Exon 20 insertion mutations in NSCLC in the first half of 2019.

“With the proceeds from recent financings we can complete a Phase 2, proof-of-concept study and continue to advance Tarloxotinib,” said Avanish Vellanki, Rain’s co-founder and chief executive officer. “Our goal is to provide Exon 20 patients with a novel treatment option that results in strong anti-tumor responses while avoiding the debilitating, dose-limiting EGFR toxicities in the gut and skin that are associated with conventional small molecule inhibitors.”

“Targeting wildtype EGFR, or wildtype EGFR-like tumors has always been very challenging with conventional small molecule inhibitors because of the abundance of EGFR in healthy tissues,” said Robert Doebele, M.D., Ph.D., co-founder of Rain Therapeutics, and associate professor of medicine and director of the Thoracic Oncology Research Initiative at the University of Colorado.  “Patients with Exon 20 lung cancer show an addiction to EGFR, however the resemblance of EGFR Exon 20 to EGFR wildtype suggests most conventional strategies will be limited by toxicity. With its novel mechanism of action, Tarlox has the potential to address this inherent, unmet challenge in Exon 20 patients.”

Rain has worldwide development and commercialization rights for Tarlox through an exclusive license to technology developed at the University of Auckland.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB inhibitor in development as a treatment for non-small cell lung cancer patients with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc., has worldwide development and commercialization rights for Tarloxotinib through an exclusive license from the University of Auckland. For more information, visit www.rainthera.com

Media Contact

Cait Williamson, Ph.D.
LifeSci Public Relations
+1.212.915.2575
cait@lifescipublicrelations.com


Download